2016
DOI: 10.1037/a0039919
|View full text |Cite
|
Sign up to set email alerts
|

Cognitive effects of modafinil in patients with multiple sclerosis: A clinical trial.

Abstract: Findings indicate that 200 mg of modafinil has the potential to improve working memory in persons with MS. These findings suggest that modafinil may enhance aspects of cognition in persons with MS and may be an effective adjunct to clinical rehabilitation interventions.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
21
0
2

Year Published

2016
2016
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 29 publications
(23 citation statements)
references
References 77 publications
(101 reference statements)
0
21
0
2
Order By: Relevance
“…FSS scores exhibited only a trend toward significant decrease, while the other scales did not show any difference [134]. Moreover, a crossover placebo-controlled study was published in 2016; it aimed to assess the impact of modafinil on fatigue and cognition in persons with MS [65]. Although the results plead for a potential role of the medication on memory performance, no effect was found on fatigue.…”
Section: Modafinilmentioning
confidence: 97%
“…FSS scores exhibited only a trend toward significant decrease, while the other scales did not show any difference [134]. Moreover, a crossover placebo-controlled study was published in 2016; it aimed to assess the impact of modafinil on fatigue and cognition in persons with MS [65]. Although the results plead for a potential role of the medication on memory performance, no effect was found on fatigue.…”
Section: Modafinilmentioning
confidence: 97%
“…To correct PFC dysfunction, we considered a newly discovered role of the mediodorsal (MD) thalamus in enhancing local functional PFC connectivity (Bolkan et al, 2017;Halassa and Kastner, 2017;Halassa and Sherman, 2019;Nakajima and Halassa, 2017;Rikhye et al, 2018aRikhye et al, , 2018bHalassa, 2018), asking whether pharmacological agents known to activate the MD might enhance PFC functional connectivity. We found that modafinil was a prime candidate; it is a known cognitive enhancer with clinical efficacy in treating cognitive symptoms across a variety of disorders (Ford-Johnson et al, 2016;Wang et al, 2017) and improving psychomotor vigilance (Czeisler et al, 2005). Unlike classical stimulants, modafinil leads to improvement on a broad range of cognitive control tasks, particularly in attention deficit hyperactivity disorder (Minzenberg and Carter, 2008;Turner et al, 2004), a comorbidity often seen in Ptchd1 deletion patients (Chaudhry et al, 2015).…”
Section: Combined Targeting Of Trn and Prefrontal Deficits In Ko Micementioning
confidence: 99%
“…Modafinil is another drug used off-label for treatment of fatigue and cognitive dysfunction in MS [ 62 , 63 ]. The effect of modafinil in MS, if any, is small and is poorly studied.…”
Section: Symptomatic Drugs Often Used For Patients With Msmentioning
confidence: 99%